文献速递乳腺癌放疗放疗物理与技术

DBCG质子试验早期乳腺癌患者选择标准:随机III期试验策略

Selection criteria for early breast cancer patients in the DBCG proton trial - The randomised phase III trial strategy.
PubMed 文献 · Clin Transl Radiat Oncol · 2021-02-04

该研究基于179例已接受局部区域IMN放疗的乳腺癌患者,回顾性修改计划以达到靶区覆盖要求后估算心脏和肺剂量,据此确定DBCG质子试验入选标准为平均心脏剂量≥4 Gy和/或同侧肺V17Gy/V20Gy≥37%,估计22%需IMN放疗患者符合条件。

要点

  • DBCG质子试验入选标准:平均心脏剂量≥4 Gy和/或肺V17Gy/V20Gy≥37%。
  • 基于179例患者估算,约22%需局部区域IMN放疗患者符合该标准。
  • 左侧计划中位平均心脏剂量3.0 Gy,右侧1.4 Gy。

核心结论

  • DBCG质子试验的患者选择标准为平均心脏剂量≥4 Gy和/或肺V17Gy/V20Gy≥37%。

研究设计与样本

  • 研究纳入179例来自18个欧洲中心、已接受局部区域IMN放疗的乳腺癌患者。
  • 若临床实际治疗计划未满足预设靶区覆盖要求,则回顾性修改计划直至达到足够覆盖。

主要发现

  • 左侧治疗计划中位平均心脏剂量为3.0 Gy(范围1.1-8.2 Gy),右侧为1.4 Gy(范围0.4-11.5 Gy)。
  • 同侧肺中位V17Gy/V20Gy(大分割/常规分割计划)为31%(范围9-57%)。
  • 采用上述阈值估计,需局部区域IMN放疗的患者中22%符合试验入选条件。

关键数值与推荐

  • DBCG放疗委员会选择平均心脏剂量≥4 Gy和/或肺V17Gy/V20Gy≥37%作为随机试验入选阈值。

临床怎么用

  • 对需局部区域IMN放疗的早期乳腺癌患者,可依据平均心脏剂量≥4 Gy和/或肺V17Gy/V20Gy≥37%筛选质子试验候选者。

局限性

  • 研究为基于179例已治疗患者的回顾性剂量估算,入选标准选择结合了质子治疗容量限制和心/肺剂量效应关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Adjuvant radiotherapy of internal mammary nodes (IMN) improves survival in high-risk early breast cancer patients but inevitably leads to more dose to heart and lung. Target coverage is often compromised to meet heart/lung dose constraints. We estimate heart and lung dose when target coverage is not compromised in consecutive patients. These estimates are used to guide the choice of selection criteria for the randomised Danish Breast Cancer Group (DBCG) Proton Trial. MATERIALS AND METHODS: 179 breast cancer patients already treated with loco-regional IMN radiotherapy from 18 European departments were included. If the clinically delivered treatment plan did not comply with defined target coverage requirements, the plan was modified retrospectively until sufficient coverage was reached. The choice of selection criteria was based on the estimated number of eligible patients for different heart and lung dose thresholds in combination with proton therapy capacity limitations and dose-response relationships for heart and lung. RESULTS: Median mean heart dose was 3.0 Gy (range, 1.1-8.2 Gy) for left-sided and 1.4 Gy (0.4-11.5 Gy) for right-sided treatment plans. Median V17Gy/V20Gy (hypofractionated/normofractionated plans) for ipsilateral lung was 31% (9-57%). The DBCG Radiotherapy Committee chose mean heart dose ≥ 4 Gy and/or lung V17Gy/V20Gy ≥ 37% as thresholds for inclusion in the randomised trial. Using these thresholds, we estimate that 22% of patients requiring loco-regional IMN radiotherapy will be eligible for the trial. CONCLUSION: The patient selection criteria for the DBCG Proton Trial are mean heart dose ≥ 4 Gy and/or lung V17Gy/V20Gy ≥ 37%.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Stick LB, Lorenzen EL, Yates ES, et al. Selection criteria for early breast cancer patients in the DBCG proton trial - The randomised phase III trial strategy. Clin Transl Radiat Oncol. 2021. PMID: 33659716. doi:10.1016/j.ctro.2021.01.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。